Nexcella
Nexcella is a clinical-stage biopharmaceutical company developing BCMA-targeted CAR-T cell therapy NXC-201 for relapsed/refractory AL Amyloidosis and Multiple Myeloma, operating as a wholly-owned subsidiary of Immix Biopharma (Nasdaq: IMMX).
- Company typePrivate
- Founded2022
- HeadquartersLos Angeles, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nexcella does
Nexcella, Inc. is a clinical-stage biopharmaceutical company developing cell therapies for relapsed/refractory AL Amyloidosis and Multiple Myeloma, with planned expansion into select immune-mediated diseases. Formed in December 2022 as a wholly-owned subsidiary of Immix Biopharma (Nasdaq: IMMX) and headquartered at 11400 West Olympic Blvd, Suite 200, Los Angeles, CA, Nexcella in-licensed its lead asset NXC-201 (formerly HBI0101), a sterically-optimized BCMA-targeted chimeric antigen receptor T-cell therapy, from the Hadassah Medical Organization. NXC-201 is being studied under the proprietary N-GENIUS discovery, development, and manufacturing platform across two clinical trials: NEXICART-1 (ex-U.S. Phase 1b/2a, NCT04720313) which had dosed 72 patients by December 2023, and NEXICART-2 (U.S. Phase 1b/2, NCT06097832) which is targeting enrollment of 40 patients with a New York City lead site. Reported clinical signals include a 100% overall response rate in AL Amyloidosis, a 95% overall response rate in Multiple Myeloma without prior BCMA exposure, zero observed ICANS or grade 4 delayed neurotoxicity, and a median cytokine release syndrome duration of one day, positioning NXC-201 as a potential first "Single-Day CRS" CAR-T therapy.
The company's technology stack is centered on a sterically-optimized CAR construct intended to reduce toxicity relative to incumbent BCMA-directed CAR-Ts, with N-GENIUS serving as the discovery, process development, and autologous manufacturing backbone. Nexcella holds FDA Orphan Drug Designation for NXC-201 in both AL Amyloidosis and Multiple Myeloma and EMA Orphan Drug Designation for AL Amyloidosis, and secured FDA IND clearance in November 2023 enabling U.S. patient dosing. The Scientific Advisory Board includes amyloidosis and multiple myeloma program directors from Boston University, Stanford, Memorial Sloan Kettering, and Columbia University, and the Board of Directors includes former Pfizer Chairman/CEO Henry McKinnell Jr., former Johnson & Johnson director Mary Sue Coleman, and former CFOs of Mylan and BioMarin.
Nexcella is pre-revenue with no product sales or licensing income disclosed. The current business model is clinical-stage R&D funded primarily through parent company Immix Biopharma and a single $8 million CLIN2 grant awarded in July 2024 by the California Institute for Regenerative Medicine. Commercial economics, if any, would accrue after potential FDA approval and would likely take the form of a one-time treatment pricing model typical of autologous CAR-T therapies, with potential administration in outpatient settings if the Single-Day CRS profile holds. The addressable market is large in aggregate — AL Amyloidosis projected to reach $6 billion by 2025 and Multiple Myeloma projected to reach $28.7 billion by 2027 — but the company's served market is currently restricted to clinical-trial enrollment at a small number of academic medical centers, with U.S. expansion as the principal near-term commercial catalyst.
Nexcella firmographics
Firmographics- Name
- Nexcella
- Legal name
- Nexcella, Inc.
- Website
- https://nexcella.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nexcella is a clinical-stage biopharmaceutical company developing BCMA-targeted CAR-T cell therapy NXC-201 for relapsed/refractory AL Amyloidosis and Multiple Myeloma, operating as a wholly-owned subsidiary of Immix Biopharma (Nasdaq: IMMX).
- Ownership category
- akta.pro rank
Nexcella industry classification
Industry- Product category
- CAR-T Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
- akta.pro secondary industries
- Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
Keywords
Where Nexcella is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Nexcella business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- CAR-T Therapy Commercialization: Nexcella is a clinical-stage biopharmaceutical company with no current revenue. The company is developing NXC-201 CAR-T therapy for AL Amyloidosis and multiple myeloma. Revenue is expected upon FDA approval and commercialization of NXC-201.
Distribution channels2 records
Marketing channels5 records
Nexcella product offering
Product offeringCore offering
Nexcella is developing NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy for the treatment of relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma. The therapy is evaluated through two clinical trials — NEXICART-1 (ex-U.S. Phase 1b/2a) and NEXICART-2 (U.S. Phase 1b/2) — and is manufactured using patients' own T cells at Nexcella's California facility via the proprietary N-GENIUS platform.
Product overview
Nexcella is a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases. The company's lead product is BCMA-targeted CAR-T therapy NXC-201, evaluated in two clinical trials: NEXICART-1 (ex-U.S. Phase 1b/2a) and NEXICART-2 (U.S. Phase 1b/2). The N-GENIUS platform supports discovery, development, and manufacturing of cell therapies. NXC-201 demonstrated 100% response rate in AL Amyloidosis and 95% response rate in Multiple Myeloma. Nexcella is a wholly-owned subsidiary of Immix Biopharma (Nasdaq: IMMX).
Differentiator
Problem solved
Functional benefit
Products and services
- NXC-201 NXC-201 is a sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy under clinical investigation for the treatment of relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma. It has demonstrated a 100% response rate in AL amyloidosis and 95% response rate in multiple myeloma across 72 patients dosed, with potential as the world's first 'Single-Day CRS' CAR-T enabling faster patient discharge and outpatient administration. Autologous CAR-T manufactured using patients' own T cells.
Quantifiable outcome
- 100% (10/10) overall response rate and 70% (7/10) complete response rate in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy (December 2023)
- +6 more outcomes
Companies that use Nexcella
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Nexcella technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Nexcella partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- U.S. GMP Cell Therapy ManufacturercoreNexcella entered into agreement with a U.S. GMP cell therapy manufacturer to supply clinical trial material for NXC-201. This supports expansion of NEXICART-1 trial to U.S. sites. The manufacturing process was transferred to the U.S. with engineering batches completed in 2023.
- Hadassah Medical OrganizationcoreNexcella in-licensed NXC-201 (formerly HBI0101) BCMA-targeted CAR-T therapy from Hadassah Medical Organization. Dr. Polina Stepensky, Director of Hadassah Medical Organization's Department of Bone Marrow Transplantation and Immunotherapy, serves as principal study investigator for NEXICART-1 clinical trial.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Nexcella competitors and assessment
Company assessmentBroad incumbents
- Bristol Myers Squibb: Markets Abecma (idecabtagene vicleucel), the first FDA-approved BCMA-directed CAR-T cell therapy for relapsed/refractory multiple myeloma. Directly competes with NXC-201 in the BCMA CAR-T space and validates the commercial CAR-T modality Nexcella is pursuing.
- Janssen (Johnson & Johnson): Co-develops and markets Carvykti (ciltacabtagene autoleucel) with Legend Biotech, a BCMA-directed CAR-T approved for multiple myeloma. Represents the primary approved BCMA CAR-T competitor to NXC-201 in the same target indication.
Direct peers
- Legend Biotech: Co-developer of Carvykti, a BCMA-targeted CAR-T cell therapy for multiple myeloma. Closely comparable to Nexcella in modality (autologous BCMA CAR-T), target indication, and clinical-stage profile, and a direct head-to-head competitor in MM.
- Autolus Therapeutics: Clinical-stage CAR-T company developing autologous CAR-T cell therapies for hematological cancers, including programs targeting BCMA. Directly comparable in modality, scale, and clinical-stage CAR-T development approach.
Emerging players
- Allogene Therapeutics: Pioneering allogeneic ('off-the-shelf') CAR-T cell therapies for hematological malignancies and solid tumors. Comparable as a next-generation cell therapy developer, though Nexcella is autologous-focused; relevant for competitive read-across on CAR-T CMC and clinical execution.
- Caribou Biosciences: Clinical-stage company developing allogeneic CAR-T cell therapies using CRISPR-based genome editing. Comparable as a next-generation cell therapy platform developer and emerging CAR-T competitor in hematology.
- Precision BioSciences: Clinical-stage cell therapy company developing allogeneic CAR-T immunotherapies (including BCMA-directed programs). Comparable as a CAR-T developer at similar clinical maturity to Nexcella, with overlapping target biology.
- Arcellx: Clinical-stage cell therapy company developing autologous CAR-T therapies, including a BCMA-directed program (CART-ddBCMA) for multiple myeloma partnered with Kite/Gilead. Directly comparable as a clinical-stage autologous BCMA CAR-T competitor.
- Atara Biotherapeutics: Clinical-stage cell therapy company developing allogeneic T-cell and CAR-T immunotherapies for hematologic malignancies and autoimmune disease. Comparable in modality (engineered T-cell therapies) and in exploring autoimmune expansion of CAR-T, a key Nexcella growth vector.
- CRISPR Therapeutics: Clinical-stage gene-editing and cell therapy company developing CRISPR-edited CAR-T cell therapies (e.g., allogeneic BCMA and CD19 programs). Comparable as a next-generation engineered cell therapy developer with overlapping BCMA CAR-T development.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Nexcella social profiles
Digital presenceNexcella compliance and trust
Trust signalCompliance3 records
Nexcella financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nexcella leadership team
Management profileNumber of profiles
Profiles12 records
Nexcella funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nexcella M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nexcella
What does Nexcella do?
Nexcella is developing NXC-201, a sterically-optimized BCMA-targeted CAR-T cell therapy for the treatment of relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma. The therapy is evaluated through two clinical trials — NEXICART-1 (ex-U.S. Phase 1b/2a) and NEXICART-2 (U.S. Phase 1b/2) — and is manufactured using patients' own T cells at Nexcella's California facility via the proprietary N-GENIUS platform.
Is Nexcella a public or private company?
Nexcella is a private company. It is classified as corporate owned and is currently operating.
When was Nexcella founded?
Nexcella was founded in 2022. It employs 1 to 10 people.
Where is Nexcella based?
Nexcella is headquartered in Los Angeles, United States, in the North America region.
How does Nexcella make money?
One revenue line is on record: CAR-T Therapy Commercialization.
Who are Nexcella's main competitors?
Broad incumbents on record are Bristol Myers Squibb and Janssen (Johnson & Johnson). Direct peers are Legend Biotech and Autolus Therapeutics. Emerging players are Allogene Therapeutics, Caribou Biosciences, Precision BioSciences, Arcellx, Atara Biotherapeutics and CRISPR Therapeutics.
Does Nexcella have an API?
No public API is recorded for Nexcella.
What industry is Nexcella in?
Nexcella's product category is CAR-T Cell Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables). Its NAICS code is 325414 and its SIC code is 2836.